Is Immunome Inc (NASDAQ: IMNM) Proving The Doubters Wrong?

Immunome Inc (IMNM) concluded trading on Thursday at a closing price of $10.51, with 4.89 million shares of worth about $51.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.97% during that period and on January 30, 2025 the price saw a gain of about 12.41%. Currently the company’s common shares owned by public are about 60.42M shares, out of which, 52.86M shares are available for trading.

Stock saw a price change of 2.84% in past 5 days and over the past one month there was a price change of -0.28%. Year-to-date (YTD), IMNM shares are showing a performance of -1.04% which decreased to -45.54% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.97 but also hit the highest price of $30.96 during that period. The average intraday trading volume for Immunome Inc shares is 828.87K. The stock is currently trading 2.86% above its 20-day simple moving average (SMA20), while that difference is down -5.93% for SMA50 and it goes to -20.79% lower than SMA200.

Immunome Inc (NASDAQ: IMNM) currently have 60.42M outstanding shares and institutions hold larger chunk of about 81.94% of that.

The stock has a current market capitalization of $656.00M and its 3Y-monthly beta is at 1.88. It has posted earnings per share of -$8.12 in the same period. It has Quick Ratio of 6.17 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMNM, volatility over the week remained 7.77% while standing at 7.32% over the month.

Stock’s fiscal year EPS is expected to rise by 17.82% while it is estimated to increase by 29.73% in next year. EPS is likely to grow at an annualized rate of 15.77% for next 5-years, compared to annual growth of -48.48% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on November 08, 2024 offering an Overweight rating for the stock and assigned a target price of $30 to it. Coverage by Piper Sandler stated Immunome Inc (IMNM) stock as an Overweight in their note to investors on May 31, 2024, suggesting a price target of $27 for the stock. On April 30, 2024, JP Morgan Initiated their recommendations, while on April 15, 2024, Guggenheim Initiated their ratings for the stock with a price target of $35. Stock get an Outperform rating from Leerink Partners on January 29, 2024.

Most Popular

Related Posts